Induction of apoptosis through targeting Bcl-2 anti-apoptotic proteins is an effective therapeutic strategy for hematologic malignancies, and Bcl-2 inhibitor venetoclax is widely used to treat AML and CLL (Ramsey et al. 2018). This evidence concerns the gene BCL2 and hematologic disorder.